Simbec-Orion worked with X on this single‐center, open‐label, fixed‐sequence study. It examined the effect of ACT‐539313 on the pharmacokinetics of orally administered midazolam to investigate the interaction potential.
You might also like
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study resultsPhase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteersLung deposition of inhaled extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide in healthy volunteers and asthma: The STORM study
Back to Clinical Trial Publications Archive